New hope for teens with severe asthma? dupilumab under the microscope
NCT ID NCT05070663
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 105 teenagers with severe uncontrolled asthma who were starting treatment with dupilumab (Dupixent). Researchers tracked their asthma control, flare-ups, and safety over one year. The goal was to see if this medication helps teens manage their condition better in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dupilumab (Dupixent)
- What this could lead to
- If successful, this could show that dupilumab helps teenagers with severe asthma breathe better and have fewer attacks.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It only follows 105 teens for one year, and asthma can vary widely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational site France
France, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?